Secukinumab shows sustained response in subjects with moderate-to-severe plaque psoriasis: a subanalysis of the ERASURE phase 3 study Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- May 1, 2015
has subject area
- 1103 Clinical Sciences (FoR)
- 1114 Paediatrics and Reproductive Medicine (FoR)
- Dermatology & Venereal Diseases (Science Metrix)